A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
- PMID: 29236639
- DOI: 10.1056/NEJMoa1614474
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults
Abstract
Background: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.
Methods: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. Immunogenicity was assessed in serum bactericidal assays that included human complement (hSBAs). We used 14 meningococcal B test strains that expressed vaccine-heterologous factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer of at least 1:4 is the accepted correlate of protection. The five primary end points were the proportion of participants who had an increase in their hSBA titer for each of 4 primary strains by a factor of 4 or more and the proportion of those who had an hSBA titer at least as high as the lower limit of quantitation (1:8 or 1:16) for all 4 strains combined after dose 3. We also assessed the hSBA responses to the primary strains after dose 2; hSBA responses to the 10 additional strains after doses 2 and 3 were assessed in a subgroup of participants only. Safety was assessed in participants who received at least one dose.
Results: In the modified intention-to-treat population, the percentage of adolescents who had an increase in the hSBA titer by a factor of 4 or more against each primary strain ranged from 56.0 to 85.3% after dose 2 and from 78.8 to 90.2% after dose 3; the percentages of young adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. Composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respectively, and those in young adults were 63.3% and 84.5%, respectively. Responses to the 4 primary strains were predictive of responses to the 10 additional strains. Most of those who received MenB-FHbp reported mild or moderate pain at the vaccination site.
Conclusions: MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was associated with more reactions at the injection site than the hepatitis A virus vaccine and saline. (Funded by Pfizer; ClinicalTrials.gov numbers, NCT01830855 and NCT01352845 ).
Similar articles
-
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.Lancet Infect Dis. 2023 Dec;23(12):1370-1382. doi: 10.1016/S1473-3099(23)00191-3. Epub 2023 Aug 11. Lancet Infect Dis. 2023. PMID: 37579773 Clinical Trial.
-
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.Vaccine. 2019 Mar 14;37(12):1710-1719. doi: 10.1016/j.vaccine.2018.11.073. Epub 2019 Feb 12. Vaccine. 2019. PMID: 30770221 Clinical Trial.
-
Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.Lancet Infect Dis. 2023 Jan;23(1):103-116. doi: 10.1016/S1473-3099(22)00424-8. Epub 2022 Sep 7. Lancet Infect Dis. 2023. PMID: 36087588 Clinical Trial.
-
Use of expanded Neisseria meningitidis serogroup B panels with the serum bactericidal antibody assay for the evaluation of meningococcal B vaccine effectiveness.Expert Rev Vaccines. 2023 Jan-Dec;22(1):738-748. doi: 10.1080/14760584.2023.2244596. Expert Rev Vaccines. 2023. PMID: 37622470 Review.
-
Meningococcal serogroup B vaccines: Estimating breadth of coverage.Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Hum Vaccin Immunother. 2017. PMID: 27960595 Free PMC article. Review.
Cited by
-
Epidemiology of Meningococcal Disease in Four South American Countries and Rationale of Vaccination in Adolescents from the Region: Position Paper of the Latin American Society of Pediatric Infectious Diseases (SLIPE).Vaccines (Basel). 2023 Dec 12;11(12):1841. doi: 10.3390/vaccines11121841. Vaccines (Basel). 2023. PMID: 38140244 Free PMC article.
-
Meningococcal B Immunisation in Adults and Potential Broader Immunisation Strategies: A Narrative Review.Infect Dis Ther. 2023 Sep;12(9):2193-2219. doi: 10.1007/s40121-023-00836-8. Epub 2023 Jul 6. Infect Dis Ther. 2023. PMID: 37428339 Free PMC article. Review.
-
Serum bactericidal activity against circulating and reference strains of meningococcal serogroup B in the United States: A review of the strain coverage of meningococcal serogroup B (MenB) vaccines in adolescents and young adults.Hum Vaccin Immunother. 2023 Dec 31;19(1):2212570. doi: 10.1080/21645515.2023.2212570. Hum Vaccin Immunother. 2023. PMID: 37257838 Free PMC article. Review.
-
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study.Pediatr Res. 2023 Sep;94(3):1035-1043. doi: 10.1038/s41390-023-02478-5. Epub 2023 Mar 10. Pediatr Res. 2023. PMID: 36899125 Free PMC article. Clinical Trial.
-
Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020.Hum Vaccin Immunother. 2022 Dec 31;18(1):2041359. doi: 10.1080/21645515.2022.2041359. Epub 2022 Feb 24. Hum Vaccin Immunother. 2022. PMID: 35201942 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical